- US-listed companies
- ACURA PHARMACEUTICALS, INC
- Income statement
ACURA PHARMACEUTICALS, INCACUR
Market cap
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | |
| Revenue | 20 | - | 0 | 1 | 9 | 4 | 3 | 0 | 3 | 4 | 2 |
| Revenue growth (%) | - | - | - | ||||||||
| Research & development | 4 | 4 | 5 | 5 | 3 | 4 | 4 | 2 | 2 | 2 | 2 |
| Selling, general & administrative | 6 | 6 | 9 | 8 | 9 | 7 | 4 | 3 | 2 | 3 | 1 |
| Operating margin (%) | - | ||||||||||
| Operating income | 11 | -10 | -14 | -12 | -4 | -7 | -5 | -4 | -1 | -1 | -1 |
| Operating expenses | 10 | 10 | 14 | 13 | 13 | 11 | 8 | 4 | 3 | 4 | 3 |
| Income before tax | 11 | -10 | -14 | -13 | -5 | -7 | -6 | -4 | -4 | -1 | -1 |
| Pretax margin (%) | 51.5 | - | -11,301.6 | -1,758.9 | -58.1 | -165.5 | -196.1 | -937.1 | -142 | -33.8 | -56.2 |
| Provision for income taxes | 0 | - | - | - | - | - | -0 | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | ||
| Net income | 10 | -10 | -14 | -13 | -5 | -7 | -6 | -4 | -4 | -1 | -1 |
| Net income margin (%) | - | ||||||||||
| Earnings per share | 0.22 | -0.2 | -0.29 | -0.27 | -0.46 | -0.62 | -0.36 | -0.18 | -0.14 | -0.04 | -0.02 |
| Diluted EPS | 0.22 | -0.2 | -0.29 | -0.27 | -0.46 | -0.62 | -0.36 | -0.18 | -0.14 | -0.04 | -0.02 |